

1 **Characteristics and Outcomes of Multisystem Inflammatory Syndrome**
2 **in Children: A Multicenter, Retrospective, Observational Cohort Study**
3 **in Mexico**

4 Nadia González-García ¹, Marco Antonio Yamazaki-Nakashimada ², Horacio
5 Márquez-González ¹, Guadalupe Miranda-Navales ³, Gonzalo Antonio Neme
6 Díaz ⁴, Sandhi Anel Prado Duran ⁵, Antonio Luévanos Velázquez ⁶, Maria F.
7 Castilla-Peon ^{7*}, Miguel Alejandro Sánchez Duran ² Martha Patricia Márquez
8 Aguirre ², Miguel Angel Villasis-Keever ³, Ranferi Aragón Nogales ⁸, Carlos Núñez
9 Enríquez ⁸, Maria Elena Martínez Bustamante ⁹, Carlos Aguilar Argüello ⁴, Jesús
10 Ramírez de los Santos ¹⁰, Alejandra Pérez Barrera ⁴, Lourdes Anais Palacios
11 Cantú ¹¹, Jesús Membrilla Mondragón ¹¹, Paloma Vizcarra Alvarado ⁶, Rodolfo
12 Norberto Jiménez Juárez ¹², Víctor Olivar López ¹ and Adrián López Chávez ¹
13

14 ¹Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico

15 ²National Institute of Pediatrics (Mexico), Mexico City, Mexico

16 ³Analysis and Synthesis of Evidence Research Unit, XXI Century National
17 Medical Center, Mexican Social Security Institute, Mexico City, Mexico

18 ⁴Hospital del Niño Dr. Rodolfo Nieto Padrón, Villahermosa, Mexico

19 ⁵HGZ No 15, Mexican Social Security Institute, Tamaulipas, Mexico

20 ⁶Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara,
21 Mexico

22 ⁷Hospital Psiquiatrico Infantil Juan N Navarro, Mexico City, Mexico

23 ⁸XXI Century National Medical Center, Mexican Social Security Institute,
24 Mexico City, Mexico

25 ⁹Department of Pediatric Infectious Diseases, Centro Médico Nacional 20 de
26 Noviembre (CMN), Mexico City, Mexico

27 ¹⁰Department of Infectious Diseases, Hospital del Niño Dr. Rodolfo Nieto
28 Padrón, Villahermosa, Mexico

29 ¹¹HGR No 270, Mexican Social Security Institute, Tamaulipas, Mexico

30 ¹²Infectious diseases, Hospital Infantil de Mexico Federico Gomez, Mexico City,
31 Mexico

32

33

34 Abstract

35

36 Multisystem inflammatory syndrome in children temporally associated with coronavirus
37 disease 2019 (MIS-C), a novel hyperinflammatory condition secondary to severe acute
38 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with severe
39 outcomes such as coronary artery aneurysm and death. This multicenter, retrospective,
40 observational cohort study including eight centers in Mexico, aimed to describe the clinical
41 characteristics and outcomes of patients with MIS-C. Patient data were evaluated using
42 latent class analysis to categorize patients into three phenotypes: toxic shock syndrome-like
43 (TSSL)-MIS-C, Kawasaki disease-like (KDL)-MIS-C, and nonspecific MIS-C (NS-MIS-
44 C). Risk factors for adverse outcomes were estimated using multilevel mixed-effects
45 logistic regression. The study included 239 patients with MIS-C, including 61 (26%), 70
46 (29%), and 108 (45%) patients in the TSSL-MIS-C, KDL-MIS-C, and NS-MIS-C groups,
47 respectively. Fifty-four percent of the patients were admitted to the intensive care unit, and
48 42%, 78%, and 41% received intravenous immunoglobulin, systemic glucocorticoids, and
49 anticoagulants, respectively. Coronary artery dilatation and aneurysm were found in 5.7%
50 and 13.2% of the patients, respectively. The rate of mortality due to SARS-CoV-2-related
51 factors was 4.6%. Delay of ≥ 10 days in hospital admission was associated with coronary
52 artery aneurysm or dilatation (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.2–2.0).
53 Age ≥ 10 years (OR 5.6, 95% CI 1.4–2.04), severe underlying condition (OR 9.3, 95% CI
54 2.8–31.0), platelet count $< 150,000/\text{mm}^3$ (OR 4.2, 95% CI 1.2–14.7), international
55 normalized ratio > 1.2 at admission (OR 3.8, 95% CI 1.05–13.9), and serum ferritin
56 concentration > 1500 mg/dL (OR 52, 95% CI 5.9–463) were risk factors for death.

57

58 **Keywords:** coronary aneurysm; coronavirus disease 2019; Mexico; multicenter study;
59 multisystem inflammatory disease; pediatric; severe acute respiratory syndrome
60 coronavirus 2;

61

62

63 1 Introduction

64

65 Multisystem Inflammatory Syndrome in Children (MIS-C), temporally associated with
66 coronavirus disease 2019 (COVID-19) also known as pediatric multisystem inflammatory
67 syndrome, is a novel hyperinflammatory condition secondary to severe acute respiratory
68 syndrome coronavirus 2 (SARS-CoV-2) infection and shares features with Kawasaki
69 disease, toxic shock syndrome, and acute COVID-19. MIS-C was first described in April
70 2020 in the United Kingdom, followed by case reports in other countries. (1,2)

71

72 The clinical case definition of MIS-C varies slightly among different health
73 agencies. (2–4) Clinical features include fever, gastrointestinal symptoms, conjunctival
74 injection, rash, and elevated inflammatory markers. (5) Potential complications include
75 shock, multi-organ failure, and myocardial and coronary artery involvement similar to
76 those observed in Kawasaki disease. (6–8) Many patients with MIS-C have evidence of
77 SARS-CoV-2 infection within several weeks before disease onset. (9–11) The estimated
78 incidence of MIS-C is 3–5 per 10,000 among individuals aged < 21 years who are infected
79 with SARS-CoV2. Studies in ethnically diverse countries reported a higher incidence of

80 MIS-C in Hispanic and Afro-descendant individuals, emphasizing the need to characterize
81 the clinical spectrum of MIS-C in specific populations. (12)

82

83 Several reports have suggested the existence of different MIS-C phenotypes,
84 including the Kawasaki disease-like (KDL)-MIS-C, the toxic shock syndrome-like (TSSL)-
85 MIS-C, as well as the nonspecific MIS-C with predominantly acute respiratory
86 involvement (NS-MIS-C). Differentiating MIS-C from acute COVID-19 and other
87 hyperinflammatory conditions can be challenging for healthcare providers. The treatment
88 approach for MIS-C includes intravenous immunoglobulin (IVIG), systemic
89 glucocorticoids, and anti-inflammatory biological agents; the efficacy of these treatments
90 relies on the timely diagnosis of MIS-C.

91

92 Despite its low prevalence, MIS-C is a serious life-threatening condition. Therefore,
93 this study aimed to examine the clinical characteristics and outcomes of KDL-MIS-C,
94 TSSL-MIS-C, and NS-MIS-C among patients with MIS-C in eight tertiary-care pediatric
95 centers in Mexico. We also performed exploratory analyses to identify factors associated
96 with coronary artery abnormalities and death.

97

98 **2. Materials and Methods**

99 **2.1 Study design**

100 This was a multicenter, retrospective, observational cohort study including patients
101 diagnosed with MIS-C in one of the eight participating pediatric tertiary care centers in
102 Mexico. Four centers were located in Mexico City: Federico Gómez Mexico Children's
103 Hospital, National Institute of Pediatrics, Siglo XXI Medical Center's Pediatrics Hospital,
104 and. Guadalajara Civil Hospital was located in Guadalajara, Jalisco; Villa Hermosa
105 Children's Hospital was located in Villa Hermosa, Tabasco, and one investigator collected
106 data on cases from the state of Tamaulipas.

107

108 The study was approved by Federico Gómez Mexico Children's Hospital
109 Institutional Review Board (approval no. HIM-2022-015) and the local ethics review board
110 of the remaining participating centers.

111

112 Probable MIS-C cases were identified by the review of medical records of patients
113 admitted to the emergency room, intensive care unit (ICU), or the general hospital ward for
114 COVID-19. Patient files were evaluated to determine if they met the MIS-C case definition
115 of the Centers for Disease Control and Prevention (Chart 1). (2)

116

117 Local investigators at participating centers collected data from the medical records
118 using REDCap (Research Electronic Data Capture) software hosted at Federico Gómez
119 Mexico Children's Hospital. Personal identifiers were kept confidential at participating
120 centers and were not registered in the general database. Data were retrieved from REDCap,
121 inconsistencies and missing data were corrected through direct communication with local
122 investigators, units of measurement were unified, and variables were converted as
123 necessary.

124

125 The worst value measured within the first three days of hospitalization was obtained
126 for laboratory parameters with more than one measurement. Life support measures
127 (respiratory support and vasopressor utilization) and the use of IVIG, systemic
128 glucocorticoids, and anticoagulant therapy were documented as primary therapeutic
129 interventions. Outcomes of interest were admission, length of ICU stay and hospitalization,
130 need for invasive mechanical ventilation, vasopressor support, myocardial depression (left
131 ventricular ejection fraction < 55%), coronary aneurysm (coronary artery diameter z-score
132 ≥ 2.5) and coronary artery dilatation (diameter z-score >2 – <2.5) on the echocardiographic
133 evaluation performed during hospitalization, and in-hospital mortality.

134
135 In the present study, severe respiratory involvement was defined as the presence of
136 infiltrates on chest X-ray or computed tomography plus the need for oxygen administration
137 with a non-rebreathing mask or a device with higher oxygen concentration. Additionally,
138 “gastrointestinal symptoms” was defined as the presence of at least one of the following:
139 abdominal pain, diarrhea, and emesis. Severe underlying conditions included cancer and
140 other immunosuppressive states, neuromuscular disability, chronic respiratory diseases
141 except for asthma, congenital cardiac disorders, and chronic kidney failure.

142 **2.2 Statistical analysis**

143
144 Descriptive analyses were conducted using STATA v.14.0 (StataCorp, Houston, TX,
145 USA). Categorical variables were reported as frequencies, and continuous variables were
146 reported as medians with interquartile ranges.

147
148 In the present study, we utilized LCA to classify 239 patients into the TSSL-PIMS,
149 KDL-PIMS, and U-PIM groups, congruent with the phenotypes identified in previous
150 studies. (13–15) LCA is a probabilistic modeling algorithm that allows clustering cases by
151 associating indicator categorical variables. Three-class LCA was conducted using the R
152 software package “poLCA” with 100 iterations to identify the clusters. The fit of each
153 model was assessed using the Bayesian information criterion score. Indicator variables used
154 in the final LCA model were the 20 features of Kawasaki disease, KDL-MIS-C, NS-MIS-
155 C-TS, and TSSL-MIS-C. (Table 1, Suppl Chart 1).

156
157 Potential heterogeneity among the participating centers was addressed by
158 determining 95% confidence intervals (CIs) of the frequencies of measured outcomes using
159 random-effects meta-analysis. Odds ratios (ORs) with 95% CIs of pooled data were
160 calculated using clustered-robust standard error adjustment. ORs adjusted for the
161 participating centers were calculated using multilevel mixed-effects logistic regression.

162 **3. Results**

163
164 Of the 264 identified patients, 6, 11, and 8 were excluded due to duplicate records,
165 lack of evidence on multi-organ involvement, and lack of evidence of previous SARS-
166 CoV-2 infection, respectively. **Tables 1** and **2** summarize the clinical characteristics and
167 outcomes of the remaining 239 patients included in the final analysis.
168
169
170

171 LCA indicated that 61 (26%), 70 (29%), and 108 (45%) of the patients exhibited the
172 clinical profiles of TSSL-MIS-C, KDL-MIS-C, and NS-MIS-C, respectively (**Table 1**). The
173 median age was higher in the TSSL-MIS-C group than in the overall cohort (11[IQR:7.1-
174 14.4] versus 7.8[IQR:2.6-13.2] years). Duration of clinical symptoms before diagnosis was
175 significantly shorter in the KDL-MIS-C group than in the other two clinical groups ($p <$
176 0.001). Additionally, the frequency of virologic positivity for acute SARS-CoV-2 infection
177 was lower ($p < 0.001$) and the frequency of serologic positivity tended to be higher ($p =$
178 0.08) in the KDL-MIS-C group than in the other two clinical groups. Only four (5.7%)
179 children in the KDL-MIS-C group had a severe underlying condition, while it was present
180 in 15(24.6%) and 22(20.4%) of the TSSL-MIS-C and NS-MIS-C, respectively. The levels
181 of plasma inflammatory markers were highest in the TSSL-MIS-C group compared with
182 the other two clinical groups.

183
184 **Table 2** describes treatments and outcomes in the total study population and the
185 three clinical groups. IVIG and systemic glucocorticoids were administered in 172 (42%)
186 and 187 (78.2%) of the patients, respectively; both treatments were more frequently (93%
187 and 91%) administered to patients in the KDL-MIS-C group. Anticoagulant therapy was
188 prescribed in 99 (41.4%) of the whole cohort and administered more frequently (60%) in
189 the TSSL-MIS-C group. Oxygen supplementation and vasopressor support were required in
190 143 (59%) and 92 (39%) of the whole cohort, respectively. Left ventricular ejection
191 fraction was below 55% in 31% of the patients, and coronary artery dilatation and
192 aneurysm were observed in 9 (5.7%) and 21(13.2%) of the patients in whom an
193 echocardiogram was performed, respectively. The median in-hospital stay for the whole
194 cohort was eight days (IQR: 5-13), and about half (54.4%) of the patients were admitted to
195 the ICU. There were 13 in-hospital deaths (5.4%), including eight patients with severe
196 underlying conditions and two who died from causes unrelated to SARS-COV-2 infection.
197 Most deaths (69%) occurred in the TSSL-MIS-C group, whereas no deaths occurred in the
198 KDL-MIS-C group.

199
200 Hematologic, neurologic, gastrointestinal, mucocutaneous, and renal dysfunction
201 were frequently observed, with variability in their frequencies among the clinical groups.
202 Prolonged coagulation time based on international normalized ratio, low platelet count,
203 gastrointestinal symptoms, and acute renal injury were more frequent in the TSSL-MIS-C
204 group (61%, 67%, 90%, and 33% of the patients, respectively) than in the other clinical
205 groups.

206
207 Coronary aneurysm or dilatation occurred in 27 (11.3%) patients. (2) After
208 adjustment for cluster effect, symptom duration > 10 days before hospital admission was
209 the only factor significantly associated with coronary artery abnormalities (OR 1.6, 95% CI
210 1.2–2.0). (**Table 3**).

211
212 Risk factors for death were age ≥ 10 years (OR 5.6, 95% CI 1.4–2.04), presence of
213 at least one underlying condition (OR 5.3, 95% CI 1.5–18.4), severe underlying condition
214 such as cancer (OR 9.3, 95% CI 2.8–31.0), platelet count $< 150,000/\text{mm}^3$ (OR 4.2, 95% CI
215 1.2–14.7), international normalized ratio > 1.2 at admission (OR 3.8, 95% CI 1.05–13.9),
216 and serum ferritin concentration > 1500 mg/dL (OR 52, 95% CI 5.9–463) (**Table 4**).

217

218 The patient population was not homogeneous among the eight participating centers.
219 Heterogeneity was high for almost all calculated treatment and outcome frequencies, and I^2 ,
220 a measure of heterogeneity, was 50% for most of the factors. Accordingly, association
221 measures were adjusted for the center effect. A significant cluster effect of the reporting
222 center was demonstrated for every evaluated factor in **Tables 3** and **4**. Disaggregated data
223 collected from the five centers with more included cases are presented in **Supplementary**
224 **Tables 1** and **2**.

225

226 **4. Discussion**

227 MIS-C, a recently characterized clinical presentation secondary to SARS-CoV-2 infection,
228 is closely associated with Kawasaki disease and toxic shock syndrome. In the present study,
229 we aimed to summarize the clinical characteristics and outcomes of patients with MIS-C
230 treated in eight pediatric tertiary care centers across Mexico. Our analyses reveal that these
231 patients share several similarities with previous case series while exhibiting some
232 differences and illustrate the presence of high heterogeneity in disease presentation and
233 outcomes among the participating centers.

234

235 It is relevant and essential to examine the clinical characteristics, disease
236 management, and outcomes of MIS-C due to the potentially severe consequences such as
237 death (16–18), damage to coronary arteries, and the toll on healthcare resources necessary
238 for its management. The present cohort's mortality rate was 4.6%, which exhibited high
239 heterogeneity across the centers, ranging from 0% to 13.5%. Similarly, the rate of coronary
240 artery abnormalities, which was 18.9% in the overall cohort, ranged from 0% to 56.3%
241 across the participating centers. Published systematic reviews estimate mortality and a rate
242 of coronary artery abnormalities ranging from 0% to 4% and from 11.6% to 21.7%,
243 respectively, in patients with MIS-C, according to the systematic reviews (19–23). In the
244 present study, coronary artery abnormalities were observed in all three clinical groups, with
245 no significant difference in frequency among the groups.

246 Among the factors that might explain the high heterogeneity in outcomes between
247 the centers included in our study and the previously published case series are (i) a wide
248 spectrum of clinical presentation in the presence of relatively nonspecific diagnostic criteria
249 that are currently used for MIS-C, (ii) variations in ethnicity and prevalence of comorbid
250 conditions, and (iii) variations in access, diagnostic paths, and therapeutic interventions
251 across different healthcare systems.

252

253 Attempts have been made to classify cases according to their predominant clinical
254 characteristics to address the lack of specific diagnostic criteria and, thus, phenotype
255 heterogeneity. In the present study, we utilized LCA to classify 239 patients into the TSSL-
256 MIS-C, KDL-MIS-C, and U-PIM groups, congruent with the phenotypes identified in
257 previous studies (13–15) In the present study, patient age was different among the clinical
258 groups; additionally, the frequency of virologic positivity was lower, and the frequency of
259 serologic positivity was higher in the KDL-MIS-C group than in the other two clinical
260 groups, suggesting different underlying pathologic mechanisms at play. Multiple pathologic
261 mechanisms have been shown to be altered in MIS-C, including the possible involvement
262 of superantigens and autoantibodies. (24) The levels of plasma inflammatory markers were
263 highest in the TSSL-MIS-C group. Additionally, the rate of life support measures and

264 mortality rate were highest in this group, as expected. The vagueness of the current clinical
265 criteria for MIS-C might be partially responsible for the wide variation in the rate of these
266 three clinical phenotypes reported by each center, suggesting a lack of clarity among
267 physicians for the threshold of clinical manifestations that eventually leads to the diagnosis
268 of MIS-C (**Supplementary Table 1**).

269
270 Demographic and preexisting medical conditions of patients in different published
271 series and clinical groups widely vary, likely accounting for some of the heterogeneity
272 observed in outcomes.

273
274 In the present study, 34.7% of the cohort had underlying conditions, which was
275 higher than that reported by Radia et al. and Antúnez et al. (25) In the present cohort,
276 severe underlying conditions were present in 17.5% of the patients varying from 3.6% to
277 23.1% across the participating centers. In addition, the frequency of patients with
278 cancer/immunosuppressive disorders or neuromuscular conditions was four to tenfold. In
279 contrast, the observed frequency of obesity (15.9%) was not as high as that reported by
280 other studies. (26) Notably, 9 of the 13 deaths in the present cohort had a severe underlying
281 condition, and the mortality was highest in the center with the highest rate of patients with
282 severe underlying conditions and the highest proportion of patients with TSSL-MIS-C.
283 These findings suggest that the high rate of severe underlying conditions might explain the
284 relatively high mortality observed in the present cohort.

285
286 Although the centers included in the present study are tertiary care reference
287 hospitals, they belong to different healthcare systems with different protocols for service
288 delivery and different resources for the management of patients during the COVID-19
289 pandemic; the difference in frequencies of IVIG utilization (from 45% to 94%) might be a
290 reflection of this aspect. In addition, there is evidence of an association between delayed
291 access to health services and worst outcomes, which might explain differences in risk for
292 bad outcomes across different geographic locations(27)Of note, the only factor that was
293 significantly associated with the development of coronary artery abnormalities after
294 adjustment for center effect was a delay of ≥ 10 days in hospital admission after the onset of
295 symptoms, a factor likely influenced by socioeconomic and geographic factors.

296
297 Factors associated with mortality were age ≥ 10 years, severe underlying condition,
298 thrombocytopenia, hyperferritinemia, and toxic shock syndrome phenotype. A study in a
299 larger cohort might reveal an association with other factors, such as IVIG use and
300 coagulopathy. Abrams et al. reported that older age, non-Hispanic black ethnicity, disease
301 onset before June 1, 2020, and high levels of serum D-dimer, troponin, atrial natriuretic
302 peptide, C-reactive protein, ferritin, and interleukin-6 were associated with ICU admission
303 in patients with MIS-C. The authors also reported abdominal pain and shortness of breath
304 as clinical findings at hospitalization admission predicting subsequent ICU admission. (28)

305
306 According to most systematic reviews, myocarditis is the most frequent
307 complication observed in patients with MIS-C; however, it was not examined in the present
308 study due to the lack of a standardized definition among the participating centers. However,
309 left ventricular ejection fraction, which was below 55% in 31% of the cohort, might be
310 considered a proxy for this outcome. In addition, we did not evaluate socioeconomic status,

311 ethnicity, and the levels of D-dimer, troponin-B, natriuretic peptide, or interleukin-6, which
312 were assessed in previous studies.

313

314 In conclusion, death was an infrequent outcome in patients with MIS-C, occurring
315 mainly in older patients with severe underlying conditions, whereas coronary aneurysms
316 were primarily associated with delayed treatment. Extrapolation of the frequency of
317 observed outcomes to the general population might not be valid due to the high frequency
318 of comorbid conditions and the heterogeneity of participating centers. The causal
319 association of risk factors with adverse outcomes should be further analyzed in longitudinal
320 studies with sufficient statistical power to adjust for multiple confounding factors found in
321 the present cohort.

322

323 **5. Conflict of Interest**

324

325 The authors declare that the research was conducted in the absence of any
326 commercial or financial relationships that could be construed as a potential conflict of
327 interest.

328

329 **6. Author Contributions**

330

331 MFPC, NGG, and HMG contributed to the conception and design of the study. HMG
332 coordinated interinstitutional collaboration. NGG organized the database. MFPC and NGG
333 performed the statistical analysis. MAYN, NGG, and MFPC wrote the first draft of the
334 manuscript. All authors contributed to data gathering and manuscript revision and read and
335 approved the submitted version.

336

337 **7. Funding**

338

339 The authors declare that this study received no funding from Hospital Infantil de Mexico
340 Federico Gómez. The funder was not involved in the study design, collection, analysis, or
341 interpretation of data.

342

343 **8. Acknowledgments**

344

345 We acknowledge the authorities of participating centers for the facilities to perform this
346 study.

347

348

349 **9. Data Availability Statement**

350

351 Datasets are available on request to NGG (nadiag.him@gmail.com)

352

353 **10. References**

354

355

356

1. Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M. SARS-CoV-2 – Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children. *Pediatrics*. 2021;146(2):1–5.

- 357 2. HAN Archive - 00432 | Health Alert Network (HAN) [Internet]. [cited 2021 Dec
358 13]. Available from: <https://emergency.cdc.gov/han/2020/han00432.asp>
- 359 3. Royal College of Paediatrics and Child Health. Guidance paediatric multisystem
360 inflammatory syndrome temporally associated with Cov-19. Royal College of
361 Paediatrics and Child Health. 2020;1–6.
- 362 4. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and
363 multisystem inflammatory syndrome in children and adolescents. *Lancet Infect Dis*.
364 2020;20(11):e276–88.
- 365 5. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and
366 multisystem inflammatory syndrome in children and adolescents. *Lancet Infect Dis*.
367 2020;20(11):e276–88.
- 368 6. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al.
369 Characteristics and Outcomes of US Children and Adolescents with Multisystem
370 Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID-
371 19. *JAMA - Journal of the American Medical Association*. 2021;325(11):1074–87.
- 372 7. Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al.
373 Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes.
374 *New England Journal of Medicine*. 2021;385(1):23–34.
- 375 8. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al.
376 Intensive care admissions of children with paediatric inflammatory multisystem
377 syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a
378 multicentre observational study. *Lancet Child Adolesc Health*. 2020;4(9):669–77.
- 379 9. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P.
380 Hyperinflammatory shock in children during COVID-19 pandemic. *The Lancet*.
381 2020;395(10237):1607–8.
- 382 10. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al.
383 Multisystem Inflammatory Syndrome in Children in New York State. *New England*
384 *Journal of Medicine*. 2020;383(4):347–58.
- 385 11. Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in
386 Geographic and Temporal Distribution of US Children with Multisystem
387 Inflammatory Syndrome during the COVID-19 Pandemic. *JAMA Pediatr*.
388 2021;175(8):837–45.
- 389 12. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al.
390 Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons
391 Infected With SARS-CoV-2. *JAMA Netw Open* [Internet]. 2021 Jun 1 [cited 2021
392 Dec 13];4(6):e2116420–e2116420. Available from:
393 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780861>

- 394 13. Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, et al.
395 Paediatric multisystem inflammatory syndrome temporally associated with SARS-
396 CoV-2 (PIMS-TS): Prospective, national surveillance, United Kingdom and Ireland,
397 2020. *The Lancet Regional Health - Europe* [Internet]. 2021 Apr 1 [cited 2021 Dec
398 13];3. Available from:
399 <http://www.thelancet.com/article/S2666776221000521/fulltext>
- 400 14. Godfred-Cato S, Abrams JY, Balachandran N, Jaggi P, Jones K, Rostad CA, et al.
401 Distinguishing Multisystem Inflammatory Syndrome in Children from COVID-19,
402 Kawasaki Disease and Toxic Shock Syndrome. *Pediatric Infectious Disease Journal*.
403 2022 Apr 1;41(4):315–23.
- 404 15. Geva A, Patel MM, Newhams MM, Young CC, Son MBF, Kong M, et al. Data-
405 driven clustering identifies features distinguishing multisystem inflammatory
406 syndrome from acute COVID-19 in children and adolescents. *EClinicalMedicine*
407 [Internet]. 2021;40:09–10. Available from:
408 <https://doi.org/10.1016/j.eclinm.2021.101112>
- 409 16. Lavery M, Salvadori M, Squires SG, Ahmed M, Eisenbeis L, Lee S, et al.
410 Multisystem inflammatory syndrome in children in Canada. *Canada Communicable*
411 *Disease Report* [Internet]. 2021 Nov 10;47(11):461–5. Available from:
412 [https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-](https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-11-november-2021/ccdrv47i11a03-eng.pdf)
413 [publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-](https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-11-november-2021/ccdrv47i11a03-eng.pdf)
414 [47/issue-11-november-2021/ccdrv47i11a03-eng.pdf](https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2021-47/issue-11-november-2021/ccdrv47i11a03-eng.pdf)
- 415 17. Baradaran A, Malek A, Moazzen N, Shaye ZA. COVID-19 associated multisystem
416 inflammatory syndrome: A systematic review and meta-analysis. Vol. 19, *Iranian*
417 *Journal of Allergy, Asthma and Immunology*. Tehran University of Medical
418 Sciences; 2020. p. 570–88.
- 419 18. Ruvinsky S, Voto C, Roel M, Fustiñana A, Veliz N, Brizuela M, et al. Multisystem
420 Inflammatory Syndrome Temporally Related to COVID-19 in Children From Latin
421 America and the Caribbean Region: A Systematic Review With a Meta-Analysis of
422 Data From Regional Surveillance Systems. Vol. 10, *Front Pediatr*. Frontiers Media
423 S.A.; 2022. p. 871765.
- 424 19. Hoste L, Paemel R van, Haerynck F. Multisystem inflammatory syndrome in
425 children related to COVID-19: a systematic review. *Eur J Pediatr* [Internet].
426 2021;180(7):2019–34. Available from: <https://doi.org/10.1007/s00431-021-03993-5>
- 427 20. Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system
428 inflammatory syndrome in children & adolescents (MIS-C): A systematic review of
429 clinical features and presentation. Vol. 38, *Paediatr Respir Rev*. W.B. Saunders Ltd;
430 2021. p. 51–7.
- 431 21. Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID-19 and
432 multisystem inflammatory syndrome in children: A systematic review and meta-
433 analysis. *Pediatr Pulmonol*. 2021 May 1;56(5):837–48.

- 434 22. Godfred-Cato S, Abrams JY, Balachandran N, Jaggi P, Jones K, Rostad CA, et al.
435 Distinguishing Multisystem Inflammatory Syndrome in Children from COVID-19,
436 Kawasaki Disease and Toxic Shock Syndrome. *Pediatric Infectious Disease Journal*.
437 2022 Apr 1;41(4):315–23.
- 438 23. Santos MO, Gonçalves LC, Silva PAN, Moreira ALE, Ito CRM, Peixoto FAO, et al.
439 Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-
440 analysis of clinical characteristics, treatment, and outcomes. Vol. 98, *Jornal de*
441 *Pediatria*. Elsevier Editora Ltda; 2022. p. 338–49.
- 442 24. Porritt RA, Binek A, Paschold L, Rivas MN, McArdle A, Yonker LM, et al. The
443 autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in
444 children. *Journal of Clinical Investigation*. 2021;131(20).
- 445 25. Antúñez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E,
446 Lavariega-Saráchaga M, Salcedo-Lozada P, et al. COVID-19 and Multisystem
447 Inflammatory Syndrome in Latin American Children: A Multinational Study. *Pediatr*
448 *Infect Dis J*. 2021;40(1):e1–6.
- 449 26. Miller A, Zambrano L, Yousaf AR, Abrams JY, Meng L, Wu MJ. Multisystem
450 Inflammatory Syndrome in Children- United States, February 2020-July 2021. *Clin*
451 *Infect Dis*. 2022;75(1):e1165–75.
- 452 27. Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in
453 Geographic and Temporal Distribution of US Children with Multisystem
454 Inflammatory Syndrome during the COVID-19 Pandemic. *JAMA Pediatr*. 2021 Aug
455 1;175(8):837–45.
- 456 28. Abrams JY, Oster ME, Godfred-Cato SE, Bryant B, Datta SD, Campbell AP, et al.
457 Factors linked to severe outcomes in multisystem inflammatory syndrome in
458 children (MIS-C) in the USA: a retrospective surveillance study. *Lancet Child*
459 *Adolesc Health*. 2021 May 1;5(5):323–31.

460

461

462

Chart 1. Case definition criteria for MIS-C	
1. Fever	
2. Elevation of inflammation markers	At least one of the following: <ul style="list-style-type: none"> • C-Reactive Protein (CRP) >5mg/L • Procalcitonin > 0.15 ng/ml • Ferritin > 300 mcg/L • Fibrinogen > 400 mg/dl • D-Dimer >560 ng/ml • Neutrophils > 7500 cells/mcl • Lymphopenia: <2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl • Albumin < 3 g/dl
3. At least two systems involved	3.1 Cardiovascular. At least one of the following: <ul style="list-style-type: none"> • Required vasoactive drug • Left ventricular ejection fraction < 55%
	3.2 Respiratory. At least one of the following: 3.3 Supplementary oxygen with non-rebreathing mask or higher oxygen concentration device. <ul style="list-style-type: none"> • Oxygen saturation <90% • Pulmonary infiltrates in chest X-Ray or Computed Tomography
	3.4 Neurologic. At least one of the following: 3.5 Glasgow score < 14 if not sedated <ul style="list-style-type: none"> • Meningismus • Seizures
	3.4 Hematologic. At least one of the following: <ul style="list-style-type: none"> • Platelets < 150 000 cells/mcl • INR > 1.2 sec
	3.5 Gastrointestinal. At least one of the following: <ul style="list-style-type: none"> • Abdominal pain • Vomit • Diarrhea • Alanine aminotransferase (ALT) > 90 U/L
	3.6 Mucocutaneous. At least one of the following: <ul style="list-style-type: none"> • Rash • Extremity edema • Desquamation • Mucosal inflammation • Conjunctivitis
	3.7 Renal Creatinine > twice the upper limit of the reference range for age
4. Hospitalization	
5. No alternative diagnosis	<ul style="list-style-type: none"> • No positive blood culture during the first 48 hours in the hospital • In uncertain cases, complete file review and consensus by an expert panel.
6. Present or recent infection by SARS-COV-2	At least one of the following <ul style="list-style-type: none"> • Positive RT-PCR¹ for SARS-CoV-2 • Positive serology for SARS-CoV-2 • Contact with a confirmed positive COVID-19 case in the last four weeks.
¹ Reverse transcriptase polymerase chain reaction.	

Tabl.1. Clinical presentation of cases with MIS-C					
	Total population (N=239)¹	Group 1 Toxic shock syndrome like (N=61)	Group 2 Kawasaki like (N=70)	Group 3 Nonspecific (N=108)	P value²
Female sex -no. (%)	103 (43.1%)	29 (47.5%)	30 (43.5%)	44 (40.7%)	0.68
Age median (IQR)	7.8(2.6-13.2)	11.0 (7.1-14.4)	6.8 (2.4-10.5)	6.2 (1.9-13.4)	<0.001
<1 y	30 (12.6%)	2 (6.7%)	6 (20%)	22 (73.3%)	
1-4 y	57 (23.9%)	7 (12.3%)	26 (45.6%)	24 (42.1%)	
5-9 y	54 (22.6%)	14 (25.9%)	19 (35.2%)	21 (38.9%)	
10-14 y	67 (28.03%)	28 (41.8%)	17 (25.4%)	22 (32.8%)	
15-18 y	31 (13.0%)	10 (32.3%)	2 (6.5%)	19 (61.3%)	
Days with symptoms before admission	6 (4-9)	7 (4-8)	4 (2-6)	7 (4-10)	<0.001
SARS-CoV2 infection evidence					
Positive RT- PCR test	105/182 (57.7%)	40/57 (70%)	16/54 (29.6%)	49/71 (69%)	<0.001
Positive rapid antigen test	46/129 (35.7%)	14/34 (41.2%)	9/44 (20%)	23/51 (45.1%)	0.03
Positive RT-PCR or rapid antigen test	130/213 (61.0%)	47/60 (78%)	23/65 (35.4%)	60/88 (68.2%)	<0.001
Positive serology	114/160 (71.3%)	24/37 (64.9%)	43/52 (82.7%)	47/71 (66.2%)	0.08
Previous comorbidities					
Obesity (BMI > 95th percentile)	38 (15.9%)	5 (8.6%)	12 (17.6%)	21 (19.4%)	0.17
Respiratory	11 (4.6%)	3 (6.7%)	2 (10.5%)	6 (9.8%)	0.76
Neuromuscular	14 (15.9%)	5 (11.1%)	3 (15.8%)	6 (9.8%)	0.69
Cardiovascular	6 (2.5%)	1(2.2%)	0	5(8.2%)	0.25
Cancer	16 (6.7%)	7 (15.6%)	0	9(14.8%)	0.18
Immunosuppression	3 (1.3%)	2 (4.4%)	0	1(1.6%)	0.74
At least one underlying condition	83 (34.7%)	24 (39.3%)	17 (24.3%)	42 (38.9%)	0.09
Severe underlying condition	41 (17.5%)	15 (24.6%)	4 (5.7%)	22 (20.4%)	0.004
Clinical presentation					
Rash	98 (41%)	30 (49.2%)	49 (70%)	19 (17.6%)	<0.001
Conjunctivitis	118 (49.4%)	32 (52.5%)	59 (84.3%)	27 (25%)	<0.001
Diarrhea	80 (33.5%)	25 (41.0%)	23 (32.9%)	32 (29.6%)	0.31
Emesis	86 (36.0%)	29 (47.5%)	29 (41.4%)	28 (25.9%)	0.01
Abdominal pain	91 (38.1%)	43 (70.5%)	33 (47.1%)	15 (13.9%)	<0.001
Rhinorrhea	57(23.8%)	22 (36.1%)	21 (30%)	14 (13%)	0.001
Respiratory dysfunction	150 (62.8%)	54 (88.5%)	25 (35.7%)	71 (65.7%)	<0.001
Anosmia/Dysgeusia	11 (4.6%)	5 (8.2%)	2 (2.9%)	4(3.7%)	0.33
Arthralgias/Myalgias	48 (20.1%)	13 (21.3%)	22 (31.4%)	13 (12.0%)	0.007
Laboratory findings					
Neutrophil count x10 ⁶ cells/mcl	8.1 (4.2-13.6)	6.5 (1.7-12.2)	9.5 (6.3-14.9)	7.7 (3.7-12.5)	0.02
Neutrophilia (>7500 cells/mcl)	130/238 (54.6%)	30 (49.2%)	46/69 (66.7%)	54 (50%)	0.06
Neutropenia (<1000 cells/mcl)	22 /239 (9.2%)	7 (11.5%)	2 (2.9%)	13 (12%)	0.07
Lymphocyte count x10 ⁶ cells/mcl	1.4 (0.6-2.6)	0.8 (0.4-1.7)	1.3 (0.9-2.2)	1.8 (0.9-3.4)	<0.001
Lymphopenia ^a	165/237 (69.6%)	44 (73.3%)	56/69 (81.2%)	65 (60.2%)	0.01
Platelets x 10 ³ cells/mcl	173 (96-315)	104 (64-165)	193 (99-329)	216(148-365)	<0.001
Platelets < 150 x 10 ³ cells/mcl	93/239 (38.9%)	41 (67.2%)	25 (35.7%)	27 (25%)	<0.001
Fibrinogen, mg/dl	427 (298-559)	508(348-617)	401(306-549)	391 (256-531)	0.24
Fibrinogen> 400 mg/dl	104/183 (56.8%)	39/58 (67.2%)	24/51 (47.1%)	41/74 (55.4%)	0.10
Ferritin, mcg/L	557 (304-1209)	828 (508-1956)	437 (213-793)	530 (252-1209)	<0.001
Ferritin> 300 mg/dl	144/191 (75.4%)	50/54 (92.6%)	39/59 (66.1%)	55/78 (70.5%)	0.001
Ferritin >1500 mg/dl	32/191 (16.7%)	14/54 (25.9%)	2/59 (3.4%)	16/78 (20.5%)	0.001
D-Dimer ng/ml	2.2 (1-5)	4.3 (1.7-9.2)	2.1 (1.0-3.8)	1.6(0.8-4.0)	<0.001
D- Dimer> 560ng/ml (0.56 ng/L)	194/219 (88.6%)	55/58 (94.8%)	57/67 (85.1%)	82/94 (87.2%)	0.178
C-reactive protein (mg/L)	60 (17-180)	15 (7-31.5)	38.7 (14.6-179.5)	22.5 (7.3-86.9)	0.85
C-reactive protein > 5mg/L	200/225 (88.9%)	50/56 (89.3%)	62/68 (91.2%)	88/101 (87.1%)	0.71
Procalcitonin ng/ml	0.85 (0.14-3.6)	1.9 (0.5-4.8)	0.5 (0.0-2.5)	0.5 (0.1-2.5)	0.005
Procalcitonin > 0.15ng/ml	126 /171 (73.7%)	49/55 (89.1%)	27/41 (65.9%)	50/75 (66.7%)	0.005
Albumin< 3g/dl	133/222 (59.9%)	51/61 (83.6%)	40/66 (60.6%)	42/95 (44.2%)	<0.001

¹N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell.

² One-sided Fisher exact test/ Mann-Whitney test for comparison between groups 1, 2, and 3. ^a Lymphopenia: <2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl

Table 2. Treatment and outcomes of cases with MIS-C

	Total sample (N=239) ¹	OR (IC 95% ²)	Between centers heterogeneity I ² (p)	Group 1 Toxic shock like (N=61)	Group 2 Kawasaki like (N=70)	Group 3 Nonspecific (N=108)	P value ³
Treatment – no. (%)							
Intravenous immune globulin	172 (42.0%)	0.76(0.58-0.94)	70.3%(<0.001)	49(80%)	65 (93%)	58 (53.7%)	<0.001
Systemic steroids	187 (78.2%)	0.81 (0.67-0.94)	54.1% (<0.001)	52(85%)	64(91%)	71(66%)	<0.001
Anticoagulation therapy	99 (41.4%)	0.35 (0.10-0.60)	96.4% (<0.001)	42(69%)	16(23%)	41(38%)	<0.001
Ventilatory support needed - no (%)							
Any oxygen supplementation	143(59.8%)	0.54(0.34-0.72)	94.5% (<0.001)	57(93.4%)	30(43%)	56(52%)	<0.001
Non-invasive mechanical ventilation	14 (5.9%)	0.07 (0.01-0.13)	62.5% (0.0)	8(13%)	0	6(5.6%)	0.006
Invasive mechanical ventilation	57 (23.9%)	0.19 (0.04-0.33)	91.7% (>0.001)	41(67.2)	0	16(15%)	<0.001
Any infiltrates in chest Rx or CT ⁴	127/224 (56.7%)	0.46 (0.22-0.71)	94.1% (<0.001)	46(75%)	19(27%)	62(57%)	<0.001
Severe respiratory involvement ⁵	82/239 (34.3%)	0.32 (0.19-0.44)	75.7 %(<0.001)	36(59%)	16(22%)	30(27%)	<0.001
Cardiovascular involvement							
LVEF ⁵ <55%	61/194 (31.4%)	0.43(0.31-0.55)	47.6% (0.13)	25(41%)	7(10%)	29(27%)	<0.001
LVEF<45%	20/194 (10.3%)	0.14 (0.06–0.22)	37.8%(0.19)	7(12%)	1(1.4%)	12(11%)	0.02
LVEF <35%	10/194 (5.2%)	0.04 (0.01-0.11)	-	3(5%)	0	7(7%)	0.05
Coronary aneurysm (z > 2.5)	21/159 (13.2%)	0.19 (0.06-0.32)	61% (0.04)	6(10%)	6 (9%)	9(8%)	0.87
Coronary dilatation (z: 2 -2.5)	9/159 (5.7%)	0.12 (0.04-0.21)	0% (0.48)	1(2%)	4(6%)	4(4%)	0.47
Vasopressor support – no (%)	92/235 (39.2%)	0.35 (0.10-0.6)	96.4% (<0.001)	48(79%)	4(6%)	40 (37%)	<0.001
Hematologic involvement							
INR > 1.2	104/233 (44.6%)	0.46 (0.30-0.62)	82.8 %(<0.001)	37(61%)	31(44%)	36(33%)	0.002
Platelets count <150 000 cell/mcl	93 (38.9%)	0.40 (0.31-0.48)	41.2% (0.12)	41(67%)	25 (36%)	27(25%)	<0.001
Neurologic involvement							
Gastrointestinal involvement	16 (6.7%)	0.06 (0.03-0.09)	0% (0.74)	3(5%)	4(6%)	9(8.3%)	0.43
Alanine Aminotransferase > 90 U/L	175 (73%)	0.74 (0.60-0.89)	89.2% (<0.001)	55(90%)	57(80%)	63(58%)	<0.001
Mucocutaneous involvement	53/203 (26.1%)	0.24 (0.15-0.33)	52.2% (0.06)	19(31%)	14(20%)	20(19%)	0.08
Acute Kidney Injury ⁶	192 (80.3%)	0.83 (0.72-0.93)	80.9 %(<0.001)	52(81%)	70(100%)	70(69%)	<0.001
ICU ⁷ admission							
ICU ⁷ admission	35/226 (15.5%)	0.14(0.09-0.20)	33.9% (0.20)	20(33%)	6 (9%)	9(8%)	<0.001
ICU ⁷ admission	130 (54.4%)	0.43 (0.17-0.69)	-	52(85%)	42(60%)	36(33%)	<0.001
Length of ICU stay, days (n=129)	4 (2-7)	-	-	5(3-8)	3(2-6)	4(2-7)	0.34
Length of Hospital stay days	8 (5-13)	-	-	10(6-17)	8(6-12)	8(4-13)	0.10
Any cause in-hospital deaths	13 (5.4%)	0.05 (0.01-0.09)	40.1 % (0.17)	9(15%)	0	4(4%)	<0.001
Died from SARS COV-2	11 (4.6%)	0.04 (0.0-0.08)	54.5% (0.09)	8(13%)	0	3(3%)	<0.001

¹N was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell. ² Exact confidence intervals by random effects metaanalysis of eight centers data. This analysis excludes centers with frequencies=0% and 100%, which explains the difference in point estimate with the first column. ³ Exact Fisher Kruskal Wallis as suitable for comparison between groups 2 and 3. ⁴Rx: chest X-ray, CT: Computed tomography. ⁵LVEF= Left ventricular ejection fraction. ⁶ Acute Kidney Injury (AKI) was defined as an increase greater than two times the upper limit of the reference range for gender and age. ⁷ ICU: intensive care unit.

Table 3. Coronary artery aneurism or dilatation associated factors.

	Frequency in the aneurism/ dilatation group N=27 (%)	Unadjusted OR (95% CI) ¹	p-value	OR adjusted for center ²	p-value
Sex (male)	19/27 (70.4%)	2.20 (0.99-4.9)	0.05	1.71 (0.63-4.58)	0.29
Age≥10 years	5/ 27(18.5%)	0.31 (0.05-2.04)	0.22	0.55 (0.17-1.80)	0.32
≥10 days with symptoms before admission	10/25 (40%)	4.16 (2.61-6.23)	<0.001	1.62 (1.19-2.04)	<0.001
Positive SARS-COV-2 RT-PCR or rapid antigen test	12/20 (60%)	0.70 (0.13-3.73)	0.67	1.11 (0.31-3.96)	0.87
Positive SARS-COV-2 serology	16/20 (80%)	2.58 (0.77-8.64)	0.125	1.45 (0.36-5.89)	0.60
Obesity (BMI > 95th percentile)	16/20 (80%)	1.04 (0.53-2.04)	0.92	1.40 (0.37-5.37)	0.63
Rash	9/27 (33%)	0.49 (0.10-2.29)	0.36	0.69 (0.25-1.91)	0.48
Conjunctivitis	17/27 (63.0%)	1.5 (0.33-6.92)	0.60	1.82 (0.57-5.77)	0.31
Gastrointestinal	16/27 (59.3%)	0.39 (0.10-1.49)	0.17	0.70 (0.22-2.15)	0.54
Severe respiratory dysfunction	11/27 (40.74%)	1.53 (0.63-3.71)	0.35	1.56 (0.59-4.18)	0.37
Arthralgias/Myalgias	2/27 (4.41%)	0.21 (0.05-0.94)	0.04	0.13 (0.02-0.67)	0.015
Mucocutaneous involvement	13/27 (48.15%)	0.35 (0.17-0.70)	0.003	0.74 (0.25-2.17)	0.59
Neutrophilia (>7500 cells/mcl)	19/27 (70.37%)	2.13 (0.82-5.58)	0.12	1.87 (0.67-5.22)	0.23
Lymphopenia ³	15/27 (55.56%)	0.52 (0.20-1.31)	0.17	0.40 (0.15-1.10)	0.08
Platelets count <150 000 cell/mcl	7/27 (25.93%)	0.48 (0.17-1.40)	0.18	0.48 (0.16-1.37)	0.17
Fibrinogen> 400 mg/dl	11/21 (52.38%)	0.68 (0.26-1.75)	0.42	0.86 (0.31-2.37)	0.77
Ferritin> 300 mg/dl	18/20 (90%)	4.39 (0.81-23.89)	0.09	4.50 (0.90-22.5)	0.07
D- Dimer> 560ng/ml (0.56 ng/L)	24/26 (92.3%)	1.64 (0.41-6.47)	0.48	0.97 (0.17-5.66)	0.98
C-reactive protein > 5mg/L	26/27 (96.3%)	2.41 (0.47-12.4)	0.29	2.68 (0.28-25.31)	0.39
Procalcitonin > 0.15ng/ml	15/23 (65.2%)	0.45 (0.27-0.76)	0.003	0.84 (0.23-3.00)	0.75
Albumin< 3g/dl	20/27 (74.07%)	1.83 (0.72-4.62)	0.20	1.62 (0.57-4.63)	0.90
INR > 1.2	14/27 (51.85%)	1.37 (0.54-3.54)	0.50	2.45 (0.86-7.00)	0.093
LVEF ⁴ <55%	8 /25 (32%)	1.25 (0.30-5.1)	0.76	1.49 (0.50-4.47)	0.45
Alanine Aminotransferase > 90 U/L	4/25 (16%)	0.53 (0.19-1.43)	0.21	0.97 (0.26-3.70)	0.97
Intravenous immune globulin	27/27 (100%)	-	-	-	-
Systemic steroids	21/27 (77.78%)	0.9 (0.16-4.93)	0.90	0.96 (0.27-3.3)	0.95
Group 1(TSS-like)	7/27 (25.9%)	1 (reference)	-	1 (reference)	-
Group 2 (Kawasaki-like)	9/27 (33.3%)	1.14 (0.29-4.45)	0.85	0.66 (0.17-2.58)	0.55
Group 3 (Unespecific presentation)	11/27 (40.7%)	1.25 (0.25-6.15)	0.78	0.59 (0.15-2.31)	0.45

¹Clustered robust standard error adjustment. ²OR adjusted for center with multilevel mixed-effects logistic regression.
³Lymphopenia: <2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl. ⁴LVEF=Left ventricular ejection fraction.

Table 4. Characteristics of deaths and associated conditions			
	Deaths (N=13)	p¹	OR (IC95%)²
Female sex -no. (%)	4	0.26	0.57 (0.17-1.96)
Age-median (IQR)	14.4 (10.6-15.3)	0.02	-
<1 y	2	-	-
1-4 y	1		
5-9 y	0		
10-14 y	6		
15-18 y	4		
Age≥10 years	10	0.008	5.64 (1.43-22.22)
Days of symptoms before admission	4 (2-5)	0.4	
More than 10 days since symptom onset	3	0.39	1.53 (0.36-6.47)
Positive RT- PCR test	8/10	0.11	3.13 (0.76-12.81)
Positive rapid antigen test	2/6	0.49	0.80 (0.17-3.69)
Positive RT-PCR or rapid antigen test	8/12	0.47	1.42 (0.38-5.28)
Positive SARS-CoV-2 serology	3/4	0.67	0.81 (0.05-13.62)
Obesity (BMI > 95th percentile)	0	0.09	-
Respiratory	1	0.58	1.08 (0.11-10.82)
Neuromuscular	3	0.06	3.73 (0.73-19.19)
Cardiovascular	0	0.63	-
Cancer	4	0.016	6.3 (1.3-30.6)
Immunosuppression	1	0.20	6.99 (0.41-119.11)
End-stage chronic renal disease	1		1.69 (0.15-18.7)
At least one underlying condition	9	0.01	5.3 (1.5-18.4)
Severe underlying condition	8	<0.001	9.3 (2.8-31.0)
On palliative care	1	-	-
Lymphocyte count x10 ⁶ cells/mcl -median (IQR)	0.6 (0.3-1.4)	0.01	-
Lymphopenia ^a	10	0.40	1.4 (0.4-5.5)
Platelets x 10 ³ cells/mcl	94 (46-191)	0.03	-
Platelets < 150 x 10 ³ cells/mcl _median (IQR)	9	0.023	4.2 (1.2-14.7)
Fibrinogen, mg/dl	94 (46-191)	0.89	-
Fibrinogen> 400 mg/dl	6/8	0.24	2.48 (0.47-13.15)
Ferritin, mcg/-L median (IQR)	3619 (2108-4752)	<0.001	-
Ferritin >300	9/9	0.04	-
Ferritin >1500	8/9	<0.001	52 (5.9-463)
Intravenous immune globulin	8	0.28	0.34 (0.08-1.44)
Systemic steroids	11	0.43	1.28 (0.25-6.61)
Anticoagulation therapy	7	0.25	1.52 (0.45- 5.15)
Coronary aneurysm (z score > 2.5)	0/2	0.75	-
Coronary dilatation (z score >2 -<2.5)	0/2	0.89	-
INR > 1.2	9	0.06	3.8 (1.05-13.9)
ICU ³ admission	11	0.02	6.5 (1.14-37.11)
Group 1(TSS-like)	9	0.001	1 (reference)
Group 2) (Kawasaki like)	0		-
Group 3 (Unespecific presentation)	4		0.15 (0.03-0.66)

1 Comparison with surviving cases with one tailed exact Fisher test or Mann-Whitney U test. ²OR adjusted by center with multilevel mixed effects logistic regression. ³ICU= Intensive care unit. ^aLymphopenia: <2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl

Table Suppl.1 Clinical presentation of cases with MIS-C for the five centers with more included cases.						
	Total population (N=239)¹	Center 1 (N=75)	Center 2 (N=52)	Center 3 (N=28)	Center 4 (N=45)	Center 5 (N=30)
Female sex -no. (%)	103 (43.1%)	39 (52%)	21 (40.4%)	6 (21.4%)	17 (38.6%)	15 (50%)
Age - median (IQR)	7.8(2.6-13.2)	11.1 (5.7-15.7)	10.6 (6.6-14.6)	7.0 (2.6-9.6)	2.4 (0.7-7.6)	3.6 (1.3-10.2)
<1 y	30 (12.6%)	5(6.7%)	3 (5.8%)	1 (3.6%)	15 (13.3%)	5 (16.7%)
1-4 y	57 (23.9%)	11 (14.7%)	8 (15.4%)	8 (28.6%)	14 (31.1%)	12 (40%)
5-9 y	54 (22.6%)	14 (18.7%)	12 (23.1%)	13 (46.4%)	8 (17.8%)	5 (16.7%)
10-14 y	67 (28.03%)	25 (33.3%)	19 (36.5%)	6 (21.4%)	8 (17.8%)	7 (23.3%)
15-18 y	31 (13.0%)	20 (26.7%)	10 (19.2%)	0	0	1 (3.3%)
Days with symptoms before admission	6 (4-9)	7 (4-7)	5 (3-9)	6 (4-7)	8 (5-14)	3.5 (2-6)
SARS-COV2 testing No. (%)						
Positive RT- PCR test	105/182 (57.7%)	57/71 (80.3%)	13/33 (39.4%)	5/18 (27.8%)	17/39 (43.6%)	6/12 (50%)
Positive rapid antigen test	46/129 (35.7%)	20/36 (55.6%)	9/34 (26.5%)	1/11 (9.1%)	7/23 (30.4%)	5/19 (26.3%)
Positive RT-PCR or rapid antigen test	130/213 (61.0%)	71/75 (94.7%)	32/52(61.5%)	4/28 (14.3%)	11/22 (50%)	7/27 (25.9%)
Positive SARS-COV-2 serology	114/160 (71.3%)	25/59 (42.4%)	16/19 (82.6%)	18/21 (85.7%)	32/33 (97.0%)	19/23 (82.6%)
Underlying medical conditions No. (%)						
Obesity (BMI > 95th percentile)	38 (15.9%)	14 (18.7%)	8 (15.4%)	4 (14.3%)	4 (8.9%)	4 (13.3%)
Respiratory	11 (4.6%)	5 (6.7%)	2 (3.9%)	0	2 (4.4%)	1 (3.3%)
Neuromuscular	14 (15.9%)	6 (8%)	4 (7.7%)	1 (3.6%)	2 (4.4%)	1 (3.3%)
Cardiovascular	6 (2.5%)	3 (4%)	2 (3.9%)	0	1 (2.2%)	0
Cancer	16 (6.7%)	7 (9.3%)	3 (5.8%)	0	4 (8.9%)	0
Immunosuppression	3 (1.3%)	2 (2.7%)	1 (1.9%)	0	4 (8.9%)	15 (50%)
At least one underlying condition	83 (34.7%)	34 (45.3%)	16 (30.8%)	1(3.6%)	15 (33.3%)	15 (50%)
Severe underlying condition	41 (17.5%)	16 (21.3%)	12 (23.1%)	1 (3.6%)	8 (17.8%)	3 (10%)
Rash	98 (41%)	36 (48%)	18 (34.6%)	17(60.7%)	3 (6.7%)	20 (66.7%)
Conjunctivitis	118 (49.4%)	30 (40%)	39 (75%)	17 (60.7%)	6 (13.3%)	21 (70%)
Diarrhea	80 (33.5%)	33 (44%)	11 (21.2%)	13 (46.4%)	10 (22.2%)	12 (40%)
Emesis	86 (36.0%)	36 (48%)	15 (28.9%)	22 (78.6%)	1 (2.2%)	11 (36.7%)
Abdominal pain	91 (38.1%)	38 (50.7%)	24(46.2%)	13 (46.4%)	2 (4.4%)	12 (40%)
Rhinorrhea	57(23.8%)	24 (32%)	25 (48.1%)	0	0	8 (26.7%)
Respiratory dysfunction	150 (62.8%)	67 (89.3%)	42 (80.8%)	8 (28.6%)	21 (46.7%)	6 (20%)
Anosmia/Dysgeusia	11 (4.6%)	7 (9.3%)	3 (5.8%)	0	1 (2.2%)	0
Arthralgias/Myalgias	48 (20.1%)	14 (18.7%)	17 (32.7%)	9 (32.1%)	0	7 (23.3%)
Respiratory support with high flow cannula or more	73 (30.5%)	39 (52%)	16 (30.1%)	4 (14.3%)	10 (22.2%)	4 (13.3%)
Neutrophil count x10 ⁶ cells/mcl	8.1 (4.2-13.6)	6.1 (1.7-9.1)	8.5(5.5-13.3)	11.1 (6.9-15.9)	5.6 (4.5-15.5)	9.7(5.9-15.5)
Neutrophilia (>7500 cells/mcl)	130/238 (54.6%)	29/74 (39.2%)	33/52 (63.5%)	20/28 (71.4%)	23/45 (51.1%)	21/30 (70%)
Neutropenia (<1000 cells/mcl)	22 /239 (9.2%)	11/75 (14.7%)	3 (5.8%)	1 (3.6%)	5 (11.1%)	1 (3.3%)
Lymphocyte count x10 ⁶ cells/mcl	1.4 (0.6-2.6)	1.5 (0.6-2.4)	0.8 (0.5-1.5)	1.2 (0.7-1.8)	2.9 (1.6-4.5)	1.4(1.0-2.1)
Lymphopenia ^a	165/237 (69.6%)	43/73 (58.9%)	42 (80.1%)	25 (89.3%)	22 (48.9%)	26 (86.7%)
Platelets x 10 ³ cells/mcl	173 (96-315)	161 (94-236)	176 (107-249)	152 (75-386)	289 (155-533)	175 (87-340)
Platelets < 150 x 10 ³ cells/mcl	93/239 (38.9%)	30/75 (40%)	20/52 (38.5%)	14/28 (50%)	11/45 (24.4%)	12/30 (40%)
Fibrinogen, mg/dl	427 (298-559)	1284 (495-3641)	452 (326-600)	404 (313-496)	250 (197-304)	313 (226-544)
Fibrinogen> 400 mg/dl	104/183 (56.8%)	52/75 (69.3%)	28/50 (56%)	14/27 (51.9%)	3/13 (23.08%)	4/10 (40%)
Ferritin, mcg/L	557 (304-1209)	618 (410-1340)	629 (457-1617)	761 (246-921)	343 (184-708)	329 (166-593)
Ferritin> 300 mg/dl	144/202 (71.3%)	53/75 (70.7%)	37/44 (84.1%)	14/19 (73.7%)	17/28 (60.7%)	17/29 (58.6%)
D-Dimer ng/ml	2.2 (1-5)	2.6 (1.1-6.4)	2.6(1.7-5.4)	1-6(1.0-3.2)	1.6(0.6-3.9)	1.4(0.4-2.4)
D- Dimer> 560ng/ml (0.56 ng/L)	194/219 (88.6%)	66/74 (89.2%)	48/49 (98%)	25/28 (89.3%)	27/32 (84.4%)	20/28 (71.4%)
C-reactive protein (mg/L)	60 (17-180)	100 (43-190)	13.9 (7.1-23.14)	168 (112-293)	33.6 (13.2-190)	101 (34-209)
C-reactive protein > 5mg/L	200/225 (88.9%)	58/63 (92.1%)	39 (76.5%)	28/28 (100%)	40/45 (88.9%)	28/30 (93.3%)
Procalcitonin ng/ml	0.85 (0.14-3.6)	1.85 (0.5-6.23)	0.06(0.01-0.53)	2.24 (0.82-6.0)	0.40 (0.14-4.5)	0.5 (1.5-1.5)
Procalcitonin > 0.15ng/ml	126/171 (73.7%)	55/62 (88.7%)	14/36 (38.9%)	15/16 (93.8%)	22/32 (68.8%)	13/17 (76.5%)
Albumin< 3g/dl	133/222 (59.9%)	45/71 (63.4%)	25(51.0%)	19/28 (67.9%)	23/37 (62.2%)	16 (55.2%)
Clinical profile						
Group 1(Kawasaki like)	61 (25.5%)	36 (48%)	15 (28.9%)	7 (25%)	2 (4.4%)	1 (3.3%)
Group 2(TSS-like)	70 (29.3%)	2 (2.7%)	22 (42.3%)	12 (42.9%)	2 (4.4%)	27 (90%)
Group 3 (Unespecific presentation)	108 (45.2%)	37 (49.3%)	15 (28.9%)	9(32.1%)	41 (91%)	2 (3.7%)

¹N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell, lymphopenia^a: <2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl

Table Suppl.2 Treatment and outcomes of cases with MIS-C for the five centers with more included cases.								
	Total sample(N=239) ¹	Center 1 (N=75)	Center 2 (N=52)	Center 3 (N=28)	Center 4 (N=45)	Center 5 (N=30)	IC 95% ²	Heterogeneity I ² (p)
Treatment – no. (%)								
Intravenous immune globulin	172 (71.2.0%)	34 (45.3%)	49 (94.2%)	25 (89.3%)	28 (62.2%)	28 (93%)	0.76(0.58-0.94)	70.3%(<0.001)
Systemic steroids	187 (78.2%)	53 (70.7%)	51 (98.1%)	21 (75%)	26 (57.8%)	29 (96.7%)	0.81 (0.67-0.94)	54.1 (<0.001)
Anticoagulation therapy	99 (41.4%)	47 (62.7%)	34 (65.4%)	1/ (3.6%)	14 (31.1%)	2 (6.7%)	0.35 (0.10-0.60)	96.4% (<0.001)
Ventilatory support needed - no (%)								
Any oxygen supplementation	143(59.8%)	61 (81.3%)	44 (84.6%)	15 (53.6%)	13 (28.9%)	5 (16.7%)	0.54(0.34-0.72)	94.5% (<0.001)
Non-invasive mechanical ventilation	14 (5.9%)	8 (10.7%)	5 (9.6%)	0	1 (2.2%)	0	0.07 (0.01-0.13)	62.5 (0.0)
Invasive mechanical ventilation	57 (23.9%)	34 (45.3%)	15 (28.9%)	2 (7.14%)	5 (11.11%)	1 (3.3%)	0.19 (0.04-0.33)	91.7 (>0.001)
Any infiltrates in chest Rx or CT ³	127/224 (56.7%)	60/71 (84.5%)	32 (61.5%)	7 (25%)	18/34(52.9%)	6 (20%)	0.46 (0.22-0.71)	94.1% (<0.001)
Severe respiratory involvement ⁴	82/239 (34.3%)	28 (37.3%)	30 (57.8%)	6 (21.4%)	10 (22.2%)	5 (16.7%)	0.32 (0.19-0.44)	75.7 %(<0.001)
Cardiovascular involvement – no (%)								
LVEF ⁵ <55%	61/194 (31.4%)	30/75 (40%)	18/37 (48.7%)	0/22 (0%)	8/27 (29.6%)	0/25 (0%)	0.43(0.31-0.55)	47.6% (0.13)
LVEF<45%	20/194 (10.3%)	6/75 (8%)	6/16.2 (37%)	0	7 /27 (25.9%)	0	0.14 (0.06–0.22)	37.8%(0.19)
LVEF <35%	10/194 (5.2%)	0	3/37 (8.1%)	0	7/27 (25.9%)	0	0.04 (0.01-0.11)	-
Coronary aneurysm (z score > 2.5)	21/159 (13.2%)	5/75 (6.7%)	5/25 (20%)	3/15 (20%)	6/16 (37.5%)	0/25 (0%)	0.19 (0.06-0.32)	61% (0.04)
Coronary dilatation (z score >2 - <2.5)	9/159 (5.7%)	0	4/25 (16%)	1/15 (6.7%)	3/16 (18.8%)	0/25 (0%)	0.12 (0.04-0.21)	0% (0.48)
Vasopressor support – no (%)	92/235 (39.2%)	41/75 (54.7%)	20/51 (39.2%)	7/27 (25.9%)	21/44(47.7%)	1/30 (3.3%)	0.35 (0.10-0.6)	96.4% (<0.001)
Hematologic involvement								
INR > 1.2	104/233 (44.6%)	38/75 (50.7%)	22/52 (42.3%)	21/28 (75%)	7/39 (18.0%)	11/30 (36.7%)	0.46 (0.30-0.62)	82.8 %(<0.001)
Platelets count <150 000 cell/mcl	93 (38.9%)	30 (40%)	20 (38.5%)	14 (50%)	11 (24%)	12 (40%)	0.40 (0.31-0.48)	41.2% (0.12)
Neurologic involvement	16 (6.7%)	5 (6.7%)	3 (5.8%)	1 (3.6%)	5 (11.1%)	1 (3.3%)	0.06 (0.03-0.09)	0% (0.74)
Gastrointestinal involvement	175 (73%)	60 (80%)	39 (75%)	26 (92.9%)	19 (42.2%)	28 (93.3%)	0.74 (0.60-0.89)	89.2% (<0.001)
Alanine Aminotransferase (ALT) > 90 U/L	53/203 (26.1%)	21/72 (29.2%)	6/30 (20%)	3/28 (10.7%)	10/35(28.6%)	12/30 (40%)	0.24 (0.15-0.33)	52.2% (0.06)
Mucocutaneous involvement	192 (80.3%)	64 (85.3%)	43 (82.7%)	25 (89.3%)	26 (57.8%)	29 (30%)	0.83 (0.72-0.93)	80.9 (<0.001)
Acute Kidney Injury, stage 2 ⁶	35/226 (15.5%)	13/69 (18.8%)	11/52 (21.2%)	5/28 (17.9%)	4/41 (9.8%)	2/29 (6.9%)	0.14(0.09-0.20)	33.9 (0.20)
ICU ⁷ admission								
Length of ICU stay-d (n=130)	4 (2-7)	4 (2-8)	4.5 (2-7)	4 (2-4)	4 (3-5)	3 (2-7)	-	-
Length of Hospital stay days								
Any cause in-hospital death	13 (5.4%)	2 (2.7%)	7 (13.5%)	0	3 (6.7%)	1 (3.3%)	0.05 (0.01-0.09)	40.1 % (0.17)
Died from COVID-19	11 (4.6%)	1 (1.33%)	7(13.5%)	0	2(4.4%)	1 (3.3%)	0.04 (0.0-0.08)	54.5% (0.09)

¹ N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell. ² Exact confidence intervals by random effects metaanalysis. This analysis excludes centers with frequencies=0% and 100%, which explains the difference in point estimate with the first column. ³ Rx: chest X-ray, CT: Computed tomography. ⁴Severe respiratory involvement was defined as oxygen requirement and infiltrates in thoracic imaging.⁵LVEF= Left ventricular ejection fraction. ⁶Acute Kidney Injury (AKI) was defined as an increase greater than two times the upper limit of the reference range for gender and age. ⁷ ICU: intensive care unit.

Supplementary Chart 1. Variables included in Latent Class Analysis

- Any cardiac involvement: cardiac arrest OR any one or more of the following findings on Echo:
 - Myocardial depression (left ventricular ejection fraction < 55%)
 - Coronary aneurysms (coronary artery diameter z-score ≥ 2.5)
 - Dilatation (z-score >2–<2.5)
 - Mitral or aortic valve insufficiency
 - Myocardial infarction
 - Other abnormalities reported
- 2. Gastrointestinal involvement: Vomiting or diarrhea
- 3. Gastrointestinal involvement: Abdominal pain
- 4. Respiratory failure (any one of the following):
 - CPAP
 - Conventional ventilation
- 5. Kawasaki features: Conjunctivitis (bilateral, bulbar, non-suppurative)
- 6. Kawasaki features: Lymphadenopathy (cervical >1.5 cm diameter)
- 7. Kawasaki features: Rash (widespread, polymorphous, not vesicular)
- 8. Kawasaki features: Lips and mucosa (red cracked lips, strawberry tongue, erythematous oral cavity)
- 9. Kawasaki features: Changes of extremities (erythema, edema of palms and soles initially)
- 10. Any other rash
 - 11. Hypotension
 - 11. Albumin – low < 3g/dl
 - 13. Raised ALT (>82 IU/L if <1yr, >56 IU/L if <3yrs, >58 IU/L if <7yrs, >72 IU/L if <13yrs, >74 IU/L if 13-15yrs)
 - 14. Raised ferritin (>300 ug/L)
 - 15. Raised D-dimers (>560 ng/ml)
 - 16. Confusion
 - 17. Creatinine (for <4yrs ≥78 umol/L, 5-11 years ≥106 umol/L, 12-15 years ≥180 umol/L)
 - 18. Platelets (<150 x 10³ cells/mm³)
 - 19. Positive SARS-CoV-2 PCR test
 - 20. Positive SARS-CoV-2 serology test

